GLP-1 receptor agonists (like Ozempic, Wegovy, and Mounjaro) were originally developed for type 2 diabetes but are now widely used for weight loss. As more women of reproductive age are taking these medications, there are some important things to understand about how they interact with fertility, pregnancy, and contraception.

Why this matters Obesity affects fertility in a big way and it can cause irregular periods, prevent ovulation, and is closely tied to PCOS. It also raises the risk of miscarriage and complications during pregnancy. So weight management is genuinely relevant to reproductive health.

The good news These medications can help women with PCOS ovulate more regularly, may improve outcomes for women doing IVF, and show early promise in protecting against certain uterine conditions, including endometrial cancer.

Before and during pregnancy These medications need to be stopped before trying to conceive, semaglutide (Ozempic/Wegovy) about 2 months before, tirzepatide (Mounjaro/Zepbound) about 1 month before. There isn’t enough safety data to use them during pregnancy.

Contraception These medications can affect how well the pill is absorbed, especially during dose increases, so a backup method is recommended during that time. IUDs and arm implants (LARCs) are the most reliable option for women on these medications.

Watch out for Rapid weight loss can lead to muscle and bone loss, so nutrition support is really important and not just calorie restriction.

Bottom line These are powerful medications with real benefits, but women who are pregnant, trying to conceive, or breastfeeding need individualized guidance and close monitoring.